Vivo Ventures VI, LLC

This profile gathers the share dealings of Vivo Ventures VI, LLC across 3 companies, led by KalVista Pharmaceuticals, Inc., Sagent Pharmaceuticals, Inc. and Eiger BioPharmaceuticals, Inc. The record holds 30 filings, for trades running from 16 September 2013 to 18 August 2016.

On the open market, the record shows 6 purchases worth €12.2M and 12 sales worth €20.0M. Sales outweigh purchases by €7.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2016 alone, the filings show 2 purchases and 4 sales.

A typical purchase (the median) is worth €1.3M.

The newest entry dates from 1 September 2016: an open-market sale of €28k, in Sagent Pharmaceuticals, Inc. The clock since the last published purchase (22 August 2016) now reads 3,731 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.